TNFRSF12A and central nervous system cancer: Mining the Cancer Genome Atlas cohort, in lower grade gliomas, TWEAK/Fn14 modified expression (7/83 cases) was associated with lower survival (10.35/75.10 months, p<10−4); in contrast, in glioblastoma cases (585 tumors), in which only 1% presented an altered expression of either TWEAK or Fn14, no significant correlation with patients' overall survival (16.57 vs 13.57 months, p<0.553) was evidenced.